Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pembrolizumab in Endometrial Carcinoma: NCT06180733 Clinical Landscape Report 2026
16 October 2026
NCT06180733 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Renal Cell Carcinoma: NCT06182735 Clinical Landscape Report 2026
16 October 2026
NCT06182735 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tenalisib in Triple Negative Breast Cancer: NCT06189209 Clinical Landscape Report 2026
16 October 2026
NCT06189209 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Mediastinal large B-cell lymphoma: NCT06188676 Clinical Landscape Report 2026
16 October 2026
NCT06188676 clinical landscape for Mediastinal large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Bendamustine Hydrochloride in Recurrent Follicular Lymphoma: NCT06191887 Clinical Landscape Report 2026
16 October 2026
NCT06191887 clinical landscape for Recurrent Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mesna in Melanoma: NCT06190249 Clinical Landscape Report 2026
16 October 2026
NCT06190249 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cemiplimab-RWLC in Melanoma, Cutaneous Malignant: NCT06190951 Clinical Landscape Report 2026
16 October 2026
NCT06190951 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT06191796 Clinical Landscape Report 2026
16 October 2026
NCT06191796 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Encorafenib in BRAF V600E Mutation-Positive Melanoma: NCT06194929 Clinical Landscape Report 2026
16 October 2026
NCT06194929 clinical landscape for BRAF V600E Mutation-Positive Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Allogeneic anti-GPC3｜IL15｜IL21 CAR-T(Baylor College of Medicine) in Hepatocellular Carcinoma: NCT06198296 Clinical Landscape Report 2026
16 October 2026
NCT06198296 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Peptide pulsed autologous Dendritic cell(Universidad Nacional de Colombia) in Triple Negative Breast Cancer: NCT06195618 Clinical Landscape Report 2026
16 October 2026
NCT06195618 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eribulin mesylate in Triple Negative Breast Cancer: NCT06202313 Clinical Landscape Report 2026
16 October 2026
NCT06202313 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.